A Phase I Study of TRN501 in Healthy Volunteers

February 4, 2025 updated by: SNLD, Ltd.

A Phase I Study to Evaluate the Safety and Pharmacokinetics of TRN501 in Healthy Adult Japanese Male Volunteers

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TRN501 following a single administration of TRN501 or placebo to healthy adult male volunteers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

72

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Japan
    • Tokyo
      • Shinjuku-ku, Tokyo, Japan, 160-0004
        • Clinical Research Hospital Tokyo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • The person who has been fully informed of the purpose and details of this clinical study prior to the start of screening and who has given his written consent to participate in this clinical study of his own free will.
  • Japanese healthy adult male volunteers between the ages of 18 and 45 on the date of obtaining written consent.
  • Those whose weight at the time of screening is 50 kg or more and Body Mass Index (BMI) between 18.5 kg/m^2 and 25.0 kg/m^2.
  • Those who have been diagnosed as healthy by the investigator in charge of the screening test and are deemed to be eligible for this study.
  • For participants who have a fertile partner or a pregnant female partner, those who agree to dual contraception by combining vasectomy or condom use for the male participant and another contraceptive method for the female partner (tubal ligation, intrauterine contraceptive device, or oral contraceptive) from the date of signing the informed consent form until the end of the study.

Exclusion Criteria:

  • Persons with disease or findings that are judged to affect this clinical study from the viewpoint of safety and/or evaluation.
  • Persons with mental, central nervous system, cardiopulmonary, hepatic, renal, hematological, metabolic, or other diseases that may affect this study.

  • A lifetime history of suicide attempts (including ongoing, previously interrupted or aborted attempts) or suicidal ideation within 6 months prior to screening. Assess using the C-SSRS. If there is a history of suicidal ideation, the timing of the ideation should be confirmed.

    • Those with abnormal resting blood pressure and pulse rate (any of the following) at screening.
    • Supine systolic blood pressure 140 mmHg or above or less than 90 mmHg
    • Supine diastolic blood pressure 90 mmHg or above or less than 50 mmHg
    • Supine pulse rate of less than 40 beats per minute or more than 100 beats per minute
    • Systolic blood pressure in the standing position (after 3 minutes in the standing position) is 20 mmHg or more lower than in the supine position, or symptoms such as dizziness are present.
  • Those with hemoglobin level less than 13.0 g/dL at screening.
  • Others who have abnormal findings in blood or urine tests and who are judged by the investigator to be unsuitable as participants for this study.
  • Those who have abnormalities in the electrocardiogram at the time of screening and who are judged by the investigator to be unsuitable as participants for this study.
  • Persons with hypersensitivity or allergy to the active ingredients or additives of TRN501 or persons with a history of severe allergies (anaphylaxis, etc.) due to other drugs.
  • Persons with chronic abnormal bowel movements (chronic constipation, chronic diarrhea, irritable bowel syndrome, etc.).
  • Persons with previous resection of the upper gastrointestinal tract (esophagus, stomach, duodenum, upper small intestine) (excluding appendicectomy).
  • Persons who have taken drugs (prescription drugs, over-the-counter drugs, herbal medicines, dietary supplements, vitamins, etc.) within one week prior to admission (or 5 times the half-life, whichever is longer), or who will be required to take such drugs by the end of the examination.
  • Smokers, or those who have quit smoking within 6 months prior to admission.
  • Persons with a history of drug abuse or alcohol dependence, or complications.
  • Those who have collected 400 mL or more of blood within 12 weeks prior to admission or 200 mL or more of blood within 4 weeks through blood donation, etc.
  • Who received all other unapproved drugs (including investigational drugs, drugs administered through clinical research, unapproved combination drugs, and new dosage forms) within 3 months (or 5 times the half-life, whichever is longer) prior to the administration of the investigational drug. However, even if the period is longer than this, those who have been judged by the investigator to be inappropriate to participate in this study in consideration of the characteristics of the previous study drug.
  • Those who are positive for either syphilis seroreaction, HBs (hepatitis B) antigen, HCV (hepatitis C virus) antibody, or HIV antigen/antibody at the time of screening.
  • Others who are judged by the investigator to be unsuitable as participants for this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Single dose 1
TRN501 - Dose 1
Drug: TRN501 - Dose 1
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 2
TRN501 - Dose 2
Drug: TRN501 - Dose 2
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 3
TRN501 - Dose 3
Drug: TRN501 - Dose 3
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 4
TRN501 - Dose 4
Drug: TRN501 - Dose 4
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 5
TRN501 - Dose 5
Drug: TRN501 - Dose 5
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 6
TRN501 - Dose 6
Drug: TRN501 - Dose 6
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 7
TRN501 - Dose 7
Drug: TRN501 - Dose 7
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Experimental: Single dose 8
TRN501 - Dose 8
Drug: TRN501 - Dose 8
Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety evaluation of TRN501: Incidents of Treatment-Emergent Adverse Events
Time Frame: For each cohort, from the administration of investigational drug or placebo to 24 hours after the administration. If any adverse event(s) continue or occur after the end of the above time frame, follow-up will be conducted up to 4 weeks.
Name of adverse event, date and time of onset, severity, seriousness, outcome, date and time of outcome, and relationship to TRN501 of all adverse events (including serious adverse events) are evaluated.
For each cohort, from the administration of investigational drug or placebo to 24 hours after the administration. If any adverse event(s) continue or occur after the end of the above time frame, follow-up will be conducted up to 4 weeks.
Safety evaluation of TRN501: Incidents of physical findings
Time Frame: 3 days and 2 nights (for each cohort)
The examination will include general findings and evaluation of the skin, eyes, ears/nose/throat, heart, chest, and abdomen. Record anything that is not normal, including those due to the subject's illness.
3 days and 2 nights (for each cohort)
Safety evaluation of TRN501: Vital sign (body temperature)
Time Frame: 3 days and 2 nights (for each cohort)
The results of vital signs will be used by the investigator to determine whether there are any safety issues continuing to participate in this study.
3 days and 2 nights (for each cohort)
Safety evaluation of TRN501: Vital sign (blood pressure)
Time Frame: 3 days and 2 nights (for each cohort)
The results of vital signs will be used by the investigator to determine whether there are any safety issues continuing to participate in this study. Blood pressure is measured in sitting state.
3 days and 2 nights (for each cohort)
Safety evaluation of TRN501: Vital sign (pulse rate)
Time Frame: 3 days and 2 nights (for each cohort)
The results of vital signs will be used by the investigator to determine whether there are any safety issues continuing to participate in this study. Pulse rate is measured in sitting state.
3 days and 2 nights (for each cohort)
Safety evaluation of TRN501: Columbia Suicide Severity Rating Scale (C-SSRS)
Time Frame: For each cohort, the day of entry (Day -1) and the day of leaving the facility (Day 2 or at the time of discontinuation).

To evaluate the safety and tolerability of TRN501, Columbia-Suicide Severity Rating Scale (C-SSRS) (Japanese version) is used to evaluates suicidal ideation and behavior.

Scale range: Yes or No response to 11 questions, with minimum to maximum range of 0 to 5. Lower score represents better outcomes. Subscales not applicable.
For each cohort, the day of entry (Day -1) and the day of leaving the facility (Day 2 or at the time of discontinuation).
Safety evaluation of TRN501: Incidents of participants with laboratory abnormality
Time Frame: For each cohort, the day of entry (Day -1) and the day of leaving the facility (Day 2 or at the time of discontinuation).
The results of laboratory test values (hematological, blood biochemical, and urinary tests) will be used by the investigator to determine whether there are any safety issues continuing to participate in this study.
For each cohort, the day of entry (Day -1) and the day of leaving the facility (Day 2 or at the time of discontinuation).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

SNLD, Ltd.

Investigators

  • Study Director: Akihisa Mori, PhD, SNLD, Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 10, 2024

Primary Completion (Actual)

September 20, 2024

Study Completion (Actual)

September 20, 2024

Study Registration Dates

First Submitted

May 21, 2024

First Submitted That Met QC Criteria

June 4, 2024

First Posted (Actual)

June 11, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 4, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • TRN501-PD101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on TRN501 - Dose 1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe